Ocifisertib

DB18746InvestigationalSmall molecule

Ocifisertib: Overview.

Mechanism: Pharmacologically active on Serine/threonine-protein kinase PLK4
Curator reviewed
Formula / weight: C₃₃H₃₄N₄O₃ · 534.66 g/mol (avg)
Also known as: (1R,2S)-2-[3-[(1E)-2-[4-[[(2R,6S)-2,6-Dimethyl-4-morpholinyl]methyl]phenyl]ethenyl]-1H-indazol-6-yl]-5′-methoxyspiro[cyclopropane-1,3′-[3H]indol]-2′(1′H)-one · (1R,2S)-2-{3-[(E)-2-(4-{[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl}phenyl)ethen-1-yl]-1Hindazol-6-yl}-5'-methoxyspiro[cyclopropane-1,3'-indol]-2'(1'H)-one · Cfi-400945 free base · Spiro(cyclopropane-1,3'-(3h)indol)-2'(1'h)-one, 2-(3-((1e)-2-(4-(((2r,6s)-2,6-dimethyl-4-morpholinyl)methyl)phenyl)ethenyl)-1h-indazol-6-yl)-5'-methoxy-, (1r,2s)-

Resolves to

Compound

Structure

InChIKeyDADASRPKWOGKCU-FVTQAUBDSA-NSMILESCOC1=CC=C2NC(=O)[C@@]3(C[C@H]3C3=CC=C4C(NN=C4\C=C\C4=CC=C(CN5C[C@H](C)O[C@H](C)C5)C=C4)=C3)C2=C1

Targets

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ocifisertib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.